e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Novel mechanisms for established drugs for asthma and COPD management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
P. Calverley, L. Fabbri, F. Martinez, U. M. Goehring, M. Brose, K. Rabe (Liverpool, United Kingdom; Modena, Italy; Ann Arbor, United States Of America; Zurich, Switzerland; Kiel, Germany)
Source:
Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Session:
Novel mechanisms for established drugs for asthma and COPD management
Session type:
Oral Presentation
Number:
3034
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Calverley, L. Fabbri, F. Martinez, U. M. Goehring, M. Brose, K. Rabe (Liverpool, United Kingdom; Modena, Italy; Ann Arbor, United States Of America; Zurich, Switzerland; Kiel, Germany). Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD. Eur Respir J 2013; 42: Suppl. 57, 3034
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Respiratory sequelae of preterm birth across the life span
Time to breathe: Challenges in the successful management of asthma during conception, pregnancy and delivery
Related content which might interest you:
Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
The relation of comorbidities with the exacerbation severity in patients with COPD
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Cardiovascular medications and mortality in patients hospitalised with acute exacerbations of COPD
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
The impact of comorbidities on the short-term serious health outcomes in hospitalized COPD patients due to exacerbation
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
COPD: Influence of patients’ nutritive status on the exacerbations rate
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
COPD on anti-GERD therapy remains at higher risk for severe exacerbation
Source: International Congress 2014 – COPD exacerbations
Year: 2014
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Gender differences in hospitalized patients with acute exacerbation of COPD
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
Vitamin D, exacerbations and hospitalizations in COPD patients
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
Frequency of COPD exacerbations and severity of COPD
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Characterization of readmissions in patients hospitalized with COPD exacerbation
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Mukoregulatory drugs in treating COPD
Source: International Congress 2014 – Predictors
Year: 2014
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015
Factors associated with cognitive dysfunction in COPD patients hospitalised with exacerbations
Source: International Congress 2014 – COPD markers
Year: 2014
Risk factors for another hospitalization in COPD patients hospitalized for exacerbation
Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases
Year: 2016
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept